Christina M Vassileva1, Sary Aranki2, J Matthew Brennan3, Tsyoshi Kaneko2, Max He4, James S Gammie5, Rakesh M Suri6, Vinod H Thourani7, Stephen Hazelrigg8, Patrick McCarthy9. 1. Division of Cardiothoracic Surgery, Southern Illinois University School of Medicine, Springfield, Illinois. Electronic address: cvassileva@siumed.edu. 2. Division of Cardiac Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Cardiology, Duke University Medical Center, Durham, North Carolina. 4. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 5. Department of Cardiac Surgery, University of Maryland Medical Center, Baltimore, Maryland. 6. Department of Cardiac Surgery, Mayo Clinic, Rochester, Minnesota. 7. Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia. 8. Division of Cardiothoracic Surgery, Southern Illinois University School of Medicine, Springfield, Illinois. 9. Division of Cardiac Surgery, Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Accurate risk assessment in patients presenting for aortic valve replacement (AVR) after prior coronary artery bypass grafting (CABG) is essential for appropriate selection of surgical versus percutaneous therapy. METHODS: We included 6,534 patients in The Society for Thoracic Surgeons (STS) Adult Cardiac Surgery Database (October 2009 through December 2013) who underwent elective, isolated reoperative AVR for aortic stenosis after prior CABG. Case-specific PROM was calculated and observed-to-expected ratios were inspected across the spectrum of risk. A cohort-specific recalibration equation was derived using logistic regression: = expit(-0.6453+0.6147*logit(PROM) -0.0709*logit(PROM)(ˆ)2), where PROM is the predicted risk of mortality. The proportion of patients reclassified as low (PROM < 4%), intermediate (4% to < 8%), high (8% to < 12%), and very high risk (≥ 12%) was calculated using the recalibration equation. The performance of the cohort-specific recalibration equation was then compared with the generic recalibration for quarterly STS reports. RESULTS: The STS online risk calculator overestimates risk for low, intermediate, and high risk categories. Using the recalibrated risk equation, a substantial proportion of patients were reclassified as the following: 25.5% from intermediate to low risk; 39.7% from high to intermediate risk; and 41.5% from very high to high risk. Comparison of the cohort-specific recalibration equation to the generic quarterly STS recalibration demonstrated very similar results. CONCLUSIONS: In patients presenting for AVR after prior CABG, the STS online risk calculator overestimates risk for all but the highest risk patients. Using a cohort-specific recalibration equation, a substantial proportion of patients would be downgraded to lower risk categories. The cohort-specific recalibration correlates well with the existing generic quarterly STS recalibration. The findings of this study support recommendations for periodic recalibration of the online risk calculator in order to facilitate clinical decision making in real time.
BACKGROUND: Accurate risk assessment in patients presenting for aortic valve replacement (AVR) after prior coronary artery bypass grafting (CABG) is essential for appropriate selection of surgical versus percutaneous therapy. METHODS: We included 6,534 patients in The Society for Thoracic Surgeons (STS) Adult Cardiac Surgery Database (October 2009 through December 2013) who underwent elective, isolated reoperative AVR for aortic stenosis after prior CABG. Case-specific PROM was calculated and observed-to-expected ratios were inspected across the spectrum of risk. A cohort-specific recalibration equation was derived using logistic regression: = expit(-0.6453+0.6147*logit(PROM) -0.0709*logit(PROM)(ˆ)2), where PROM is the predicted risk of mortality. The proportion of patients reclassified as low (PROM < 4%), intermediate (4% to < 8%), high (8% to < 12%), and very high risk (≥ 12%) was calculated using the recalibration equation. The performance of the cohort-specific recalibration equation was then compared with the generic recalibration for quarterly STS reports. RESULTS: The STS online risk calculator overestimates risk for low, intermediate, and high risk categories. Using the recalibrated risk equation, a substantial proportion of patients were reclassified as the following: 25.5% from intermediate to low risk; 39.7% from high to intermediate risk; and 41.5% from very high to high risk. Comparison of the cohort-specific recalibration equation to the generic quarterly STS recalibration demonstrated very similar results. CONCLUSIONS: In patients presenting for AVR after prior CABG, the STS online risk calculator overestimates risk for all but the highest risk patients. Using a cohort-specific recalibration equation, a substantial proportion of patients would be downgraded to lower risk categories. The cohort-specific recalibration correlates well with the existing generic quarterly STS recalibration. The findings of this study support recommendations for periodic recalibration of the online risk calculator in order to facilitate clinical decision making in real time.
Authors: Timothy S Lancaster; Matthew R Schill; Jason W Greenberg; Chawannuch Ruaengsri; Richard B Schuessler; Jennifer S Lawton; Hersh S Maniar; Michael K Pasque; Marc R Moon; Ralph J Damiano; Spencer J Melby Journal: Ann Thorac Surg Date: 2017-12-19 Impact factor: 4.330
Authors: Oliver K Jawitz; Brian C Gulack; J Matthew Brennan; Dylan P Thibault; Alice Wang; Sean M O'Brien; Jacob N Schroder; Jeffrey G Gaca; Peter K Smith Journal: Am Heart J Date: 2020-02-08 Impact factor: 4.749
Authors: Oliver K Jawitz; Brian C Gulack; Maria V Grau-Sepulveda; Roland A Matsouaka; Michael J Mack; David R Holmes; John D Carroll; Vinod H Thourani; J Matthew Brennan Journal: JACC Cardiovasc Interv Date: 2020-06-10 Impact factor: 11.195
Authors: Sharaf-Eldin Shehada; Yacine Elhmidi; Öznur Öztürk; Markus Kasel; Antonio H Frangieh; Fanar Mourad; Jaroslav Benedik; Jaafar El Bahi; Mohamed El Gabry; Matthias Thielmann; Heinz Jakob; Daniel Wendt Journal: Cardiol Res Pract Date: 2018-04-05 Impact factor: 1.866